Balaxi Pharmaceuticals Limited · NSE:BALAXI
Balaxi Pharmaceuticals — Q1 FY24 Earnings Presentation
22 slides from Balaxi Pharmaceuticals's earnings presentation, Aug 3, 2023
Slide 1: Cover letter to National Stock Exchange
August 03, 2023 To, Listing Department, National Stock Exchange of India Limited Exchange Plaza, Plot No C-1, Block G, Bandra Kurla Complex, Bandra (E), Mumbai – 400051 NSE Symbol: BALAXI Dear Sir/Madam, Subject: Investor Presentation In compliance with Regulation 30 of SEBI (Listing Obligations and
Slide 2: Balaxi Pharmaceuticals Limited Investor Presentation
Balaxi Pharmaceuticals Limited Branded IPR-driven Pharma Player in Frontier Markets Investor Presentation
Slide 3: Disclaimer
_j_ _ _ __ Disclaimer I I I I I I I Certain statements in this document may be forward-looking statements. Such forward-looking statements are subject to certain risks and uncertainties like regulatory changes, local political or economic developments, technological risks, and many other factors tha
Slide 4: Contents
__j_ _ _ __ Contents I I I I I I I 04 Corporate Snapshot 14 Financial Highlights 20 Strategic Roadmap • • • • • • • • • • • • • • • -r '' '' • • ' ' Balaxi 3
Slide 5: Bridging the Supply Gap in Frontier Markets
_j_ __ Bridging the Supply Gap in Frontier Markets • • • • • • • • • • Branded IPR-based pharma Presence in OTC segments including • • • • company strong branded generics portfolio • • • • • • Frontier markets leadership in Targeting top-2 position in each Latin America and Africa geography Vast por
Slide 6: Successful Produce, Stock, Sell Business Model
_j_ _ _ __ Successful Produce, Stock, Sell Business Model I I I I I I I Established operations: Guatemala (Latin America), Dominican Republic (Caribbean) and Expansion initiated: Markets Angola (Africa) Nicaragua, Ecuador, Chile (Latin America) New operations: Hondurus, El Salvador and Central Afric
Slide 7: Key Success Factors
_j_ _ _ __ • • Key Success Factors • • I I I I I I I • • • • • • • • • • • • Market Selection Methodology • • • • • • Focus on countries with high-potential economic growth framework • • Identify non-English speaking countries with similar characteristics Low competitive intensity and potentia
Slide 8: Transition from Asset Light to Asset Right
_l_ _ _ __ • • • • Transition from “Asset Light” to “Asset Right” I • • • • I I I I I I • • • • • • • • • • • • • • Marketing and Market Research Product Product Manufacturing Distribution Identification Registration Existing Operations New Manufacturing Unit As a part of its corporate evolution, Ba
Slide 9: Investment in Manufacturing Facilities
_j_ _ _ __ • • • • Investment in Manufacturing Facilities I I I I I • • • • I I • • • • • • • • • • • • • • Setting up its first pharmaceutical formulation manufacturing unit • • General Oral Solid Dosage (OSD) and Liquid Injection formulations Targeting demand for high quality products in Latin Ame
Slide 10: Global Footprint
Global Footprint Global Footprint ...• Guatemala .---::-11. r Dominican Republic Honduras Portugal India China • • • Existing Market Targeted Expansion Product Sourcing Regions El Salvador ·------. ragua Angola . . . t .. . ... Existing/targeted markets have aggregate GDP of$ 400 billion and pharma
Slide 11: Key Milestones
_j_ _ _ _ Key Milestones I I I I I • • • • I I • • • • • • • • • • • • • • • • • • • • • • • • • • Started business supplying • • • • white labelled products to customers in Africa Diversified supply chain by Products were sourced from sourcing pharma products Set-up central distribution WHO GMP cer
Slide 12: Corporate Structure
_j_ _ _ __ Corporate Structure I I I I I I I Balaxi Pharmaceuticals Limited Balaxi Global DMCC, Dubai (WOS) I I I I r-----------------r------------------,--------------L-~------------------i _______________ i ________________ _ I I I I I I I I I I I I I I I I I I T T T T T T Balaxi Balaxi Balaxi Bal
Slide 13: Experienced Board of Directors
_j_ _ _ __ Experienced Board of Directors I I I I I I I Ashish Maheshwari Minoshi Maheshwari Kunal Bhakta Chairman & Managing Director Non-Executive Director Independent Director Founder of the company, first Co-founder, 20 years of Chartered Accountant with 15 years’ generation entrepreneur, rich e
Slide 14: Dynamic Leadership Team
_j_ _ _ __ • • • • • • Dynamic Leadership Team I I I I I I • • • • • • I Ashish Maheshwari Amol Mantri Chairman & Managing Director CFO Founder of the company, first generation Qualified Chartered Accountant and Certified Public entrepreneur, qualified Chartered Accountant Accountant from USA Commen
Slide 15: Financial Highlights
_J- - - - 1 I I I I I I FINANCIAL HIGHLIGHTS Balaxi 14
Slide 16: Management's Comments
_j_ _ _ __ • • • • • • • • • • Management’s Comments I I I I I • • • • I I • • • • • “Q1 was an exceptionally challenging quarter for Balaxi. We witnessed unprecedented economical chaos in terms of currency depreciation in our biggest and oldest market of Angola, where local currency weekend in reco
Slide 17: Financial Performance (Consolidated)
_j_ _ _ __ Financial Performance (Consolidated): I I I I I • • I I • • • • • • • • Particulars (INR Crore) Q1FY24 Q1FY23 YoY • • • • • • • • Revenue 65.96 82.78 (20.3%) • • Gross Profit 25.64 34.52 (25.7%) Gross Margin % 38.9% 41.7% (280 bps) EBITDA Before Exceptional Item 7.83 17.03 (54%) EBITDA Ma
Slide 18: Pharma Product Mix – Q1 FY24
_j_ _ _ _ • • Pharma Product Mix – Q1 FY24 I I I I I I • • • • I • • • • • • • • Geographies Products • • • • • • Shareholders’ Debt Fixed Assets Working Capital Funds 38% 46% ■ Africa* ■ Branded 54% ■ LATM** ■ Generics 62% Dosage Forms Therapeutic Areas 11% ■ Tablets Antibiotics 33% 47% ■ ■ Injecta
Slide 19: Historical Financial Performance (Consolidated)
_j_ _ _ __ Historical Financial Performance (Consolidated) I I I I I • • I I • • • • • • • • • • • • . . • • • • Particulars (INR Crore) FY23 FY22 YoY • • Revenue 336.43 279.39 +20.4% Gross Profit 134.01 83.79 +59.9% Gross Margin % 39.8% 30.0% +980 bps EBITDA 59.17 55.18 +7.2% EBITDA Margin % 17.6%
Slide 20: Pharma Product Mix – FY23
_j_ _ _ _ • • Pharma Product Mix – FY23 I I I I I I • • • • I • • • • • • • • Geographies Products • • • • • • Shareholders’ Debt Fixed Assets Working Capital 40% Funds 37% ■ Africa* ■ Branded ■ LATAM** ■ Generics 60% 63% Dosage Forms Therapeutic Areas 10% ■ Tablets Antibiotics 33% 41% ■ ■ Injectabl
Slide 21: Core Strategy: Enter, Expand & Excel
_j_ _ _ __ • • • • Core Strategy: Enter, Expand & Excel I I I I I • • • • I I • • • • • • • • • • • • Balaxi in 2020: Business Consolidation • • Presence across Angola, Guatemala and Dominican Republic • • Effective and efficient supply chain model consisting of 38 warehouses and a fleet of owne
Slide 22: Thank You
Balaxi Pharmaceuticals Limited Plot No. 409, H.No. 8-2-293, 2nd Floor Maps Towers, Jubilee Hills, Road No:81,Hyderabad. Telangana CIN: L25191TG1942PLC121598 Company Investor Relations contact ® Sunny Purohit • • ~ +91-40-2355-5300 • • • • • • • • 8 sunny@balaxi.com • • • • @ www.balaxipharma.in • •
Balaxi Pharmaceuticals — Q1 FY24 Earnings Presentation on 6ix